Design of the randomized, placebo-controlled evolocumab for early reduction of LDL-cholesterol levels in patients with acute coronary syndromes (EVOPACS) trial.
作者:
主题词
急性冠状动脉综合征(Acute Coronary Syndrome);抗体, 单克隆(Antibodies, Monoclonal);抗胆固醇血症药(Anticholesteremic Agents);胆固醇, LDL(Cholesterol, LDL);剂量效应关系, 药物(Dose-Response Relationship, Drug);双盲法(Double-Blind Method);可行性研究(Feasibility Studies);女(雌)性(Female);随访研究(Follow-Up Studies);人类(Humans);高胆固醇血症(Hypercholesterolemia);男(雄)性(Male);中年人(Middle Aged);前瞻性研究(Prospective Studies);时间因素(Time Factors);治疗结果(Treatment Outcome)
DOI
10.1002/clc.23112
PMID
30421481
发布时间
2021-01-09
- 浏览13

Clinical cardiology
1513-1520页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文